CPT® Code 87880

Last Updated: January 2026 | Verified for 2026 AMA, CPT & CMS Guidelines

Quick Reference: CPT 87880

• What it is: CPT 87880 reports the rapid Group A Streptococcus (GAS) antigen test performed by immunoassay with direct visual (optical) reading—the classic “lateral flow”/card-style rapid strep test used to diagnose streptococcal pharyngitis in real time .
• CLIA-waived billing: Many commonly used rapid strep kits are CLIA-waived. For Medicare claims when performed as a waived test, append modifier QW (87880QW), and include the site’s CLIA number on the claim as required .
• When to test: Payers generally expect testing for patients with symptoms of pharyngitis and clinical features consistent with GAS; many policies discourage testing for viral presentations or asymptomatic screening .
• Do not double-test the same organism by multiple methods: Medicare’s NCCI policy broadly restricts separate payment for testing a single microorganism from the same site by more than one methodology in most cases. This is a frequent denial driver when clinics bill both a rapid antigen test and a molecular strep test for the same encounter .
• Negative in children: Clinical pathways and payer policies commonly support a confirmatory throat culture after a negative RADT in pediatric patients, while adults often do not require confirmation unless clinical suspicion is high . CPT 87880 is one of the highest-volume point-of-care laboratory codes in outpatient medicine because it supports immediate antibiotic decision-making for suspected Group A streptococcal pharyngitis. The operational reality is simple—swab the throat, run a kit, read a line—but coding compliance is not always simple because payers closely manage (1) CLIA-waived billing requirements, (2) duplicate-method billing (antigen plus NAAT for the same target), and (3) documentation that links the test to a symptomatic indication.

This guide is written for 2026 billing behavior: what 87880 represents, when QW is required, how NCCI policy affects same-day testing, how common payer policies treat reflex culture, and how to document the service so the claim is defensible in both pre- and post-payment review.

1. Clinical Use and Test Definition

CPT 87880 is defined as infectious agent antigen detection by immunoassay with direct optical (visual) observation for Streptococcus, group A. In practice, this is the rapid antigen detection test (RADT) that detects GAS antigen from a throat swab and yields a result within minutes. Coding guidance emphasizes that 87880 is used for visually read rapid strep kits where the interpretation is made by sight (for example, a colored line appearing on the test device) .

Clinical purpose: The test is primarily used to differentiate GAS pharyngitis from viral pharyngitis so that antibiotics are prescribed only when indicated. This supports antimicrobial stewardship and aligns with quality expectations in pediatrics and primary care.

Positive vs. negative results and clinical workflow

A positive rapid strep test supports a diagnosis of streptococcal pharyngitis (often coded clinically as J02.0). A negative test does not necessarily rule out GAS in children because RADT sensitivity is imperfect, so many clinical pathways recommend confirmatory throat culture in pediatric patients with compatible symptoms. Payer policies often reflect this standard approach and explicitly allow reflex culture after negative RADT in children .

Because the RADT is used to guide treatment in the same encounter, it is commonly performed in offices, urgent care, and school-based clinics. The key compliance point is that the billed code must match the methodology. If the test is performed using a different technology (for example, an instrument/analyzer-based immunoassay rather than a visually read device), the correct CPT may differ. CMS guidance describing waived tests and associated coding updates illustrates how methodology-specific codes and waivers are maintained over time .

Methodology rule: Code selection should reflect how the test is performed and interpreted (visual vs. instrumented; antigen vs. NAAT), not merely that the patient “had a strep test.” Method mismatch is a common audit finding in point-of-care testing programs.

2. CLIA Waiver and Certification Requirements

CLIA (Clinical Laboratory Improvement Amendments) applies to any testing of human specimens. Many rapid strep antigen kits are designated CLIA-waived, meaning they may be performed in settings holding a CLIA Certificate of Waiver (for example, physician office labs and urgent care centers) when the test is used according to manufacturer instructions. CMS maintains a waived test list and associated guidance that clinics use to confirm whether a specific test system is waived for a given CPT .

Medicare billing: why QW matters

For Medicare billing, waived status is not only a compliance issue—it is also a claims-processing requirement. Medicare generally expects modifier QW on claims for CLIA-waived tests when the site is billing under a waiver certificate. CMS resources and payer-facing implementation instructions support the use of QW to identify waived testing on the claim . If QW is omitted, claims are commonly denied for CLIA-related reasons even when the test was properly performed.

Operational best practice: Many organizations set their billing system to auto-append QW to codes that are routinely performed as waived point-of-care tests (including 87880 in many settings) to reduce preventable denials. Guidance from billing workflow sources explains how QW is used across multiple CPTs and why payer edits are sensitive to it .

CLIA number inclusion

In addition to modifier use, ensure the site’s CLIA number is submitted on the claim in the appropriate field. Even when the test is straightforward, missing the CLIA identifier can block payment. The CMS waived list resource is frequently used in audits to validate that the billed code was eligible for waived performance with the reported CLIA certification .

3. Medicare and Commercial Payer Billing Guidelines

Medicare generally covers 87880 when the test is ordered by a treating clinician and is reasonable and necessary for a symptomatic condition such as pharyngitis. Commercial payers typically apply similar rules but may add policy constraints about when testing is appropriate (for example, discouraging testing for presentations that look viral).

Coverage expectations: symptomatic pharyngitis

Commercial medical policies commonly specify that strep testing is intended for patients with symptoms consistent with GAS pharyngitis and not for screening asymptomatic individuals. A current Blue Cross NC policy provides explicit coverage criteria and limitations, including circumstances where testing is considered not medically necessary . In practical terms, diagnoses like acute pharyngitis/tonsillitis, sore throat, fever with pharyngeal findings, and related clinical documentation are the typical “coverage-compatible” context for 87880.

Frequency and “one test per encounter” behavior

For most payers, one rapid strep test per encounter (or per day) is the expected norm. If clinical suspicion remains high after a negative RADT—especially in pediatric patients—coverage logic typically supports confirmatory culture rather than repeating the same rapid antigen test. Policies that explicitly allow reflex culture after negative RADT in children are designed to prevent unnecessary repeat RADTs and to align billing with guideline-based care .

Key denial pattern: antigen + NAAT on the same day

One of the most common denial drivers is billing multiple methodologies for the same organism from the same site on the same day. Medicare’s NCCI manual states a general policy prohibiting separate payment for testing for a single microorganism from the same site by more than one methodology in most cases . This becomes relevant when an office performs a RADT (87880) and also bills a molecular strep test (NAAT) performed the same day for the same sore-throat episode. Many payers treat this as duplicative unless there is a clearly documented, policy-supported rationale.

Practical payer logic: If the goal is to establish whether GAS is present, most payers will reimburse one clinically appropriate method (RADT with reflex culture, or NAAT, or culture) rather than multiple methods performed in parallel. When both are billed, expect bundling edits or “not medically necessary” denials unless documentation is unusually strong and policy-justified .

4. Modifier Use and NCCI Edits

Modifier use for 87880 is usually simple: QW is the dominant modifier in CLIA-waived settings. Other modifiers may be needed when multiple distinct tests are performed during the same encounter and payer edits would otherwise bundle or deny one of them.

Modifier QW (CLIA-waived test)

Append QW when billing Medicare for a waived rapid strep antigen test performed under a CLIA Certificate of Waiver. CMS maintains waiver information and publishes updates that clarify which tests are recognized as waived and how they should be billed . Operational billing guidance also explains that QW acts as a claims signal to satisfy Medicare’s CLIA processing edits .

Modifier 59 (or X{EPSU} subset modifiers) for distinct tests

Modifier 59 (or a more specific X-modifier such as XU) may be appropriate when a payer edit would otherwise treat two codes as duplicative, but the services are truly distinct (different analytes, different specimens, or different clinical reasons). Multi-test respiratory encounters are common: for example, a sore-throat visit where the provider performs flu and COVID testing in addition to rapid strep. Practical billing examples emphasize checking edits and using modifier 59 when justified to signal distinct procedures and avoid inappropriate bundling .

When using 59/X modifiers, documentation should clearly distinguish the tests by specimen and target (for example, nasal swab for flu/COVID, throat swab for strep) and should support why each test was reasonable given symptoms.

NCCI duplicate-method restriction: the core rule to remember

The NCCI policy principle that matters most for 87880 is the “single organism, single site, one method” concept. Medicare’s NCCI manual explains that separate payment is generally prohibited when testing the same microorganism from the same site by more than one methodology, with limited exceptions described in the manual . In day-to-day practice, this means avoid billing 87880 and a molecular strep test for the same throat swab episode unless you have a payer-accepted rationale and expect scrutiny.

5. Documentation and Result Interpretation Standards

For point-of-care testing, documentation quality is often the difference between routine payment and avoidable denials. A complete 87880 record should make it easy for a reviewer to answer four questions: Why was the test needed? What test was performed? What was the result? How did the result influence care?

Minimum documentation elements

• Indication: Symptoms and exam findings consistent with pharyngitis (for example sore throat, fever, tonsillar exudates, tender nodes, absence of cough) and any risk factors relevant to payer policies .
• Test identification: “Rapid Group A Strep antigen” performed as point-of-care test, including date/time. If your workflow uses an analyzer or a different method, ensure the record reflects it so the CPT code matches methodology.
• Result: Positive/negative/invalid, with a recorded value and (ideally) the POCT module output attached to the chart.
• Action taken: For positive results, diagnosis and antibiotic decision; for negative results, symptomatic care and (for children when indicated) reflex culture plan consistent with policy expectations .

Documenting reflex culture after a negative RADT in pediatrics

If a culture is ordered after a negative rapid test in a child, document that the culture is being performed to confirm a negative RADT. Policies that explicitly support this reflex pathway provide a strong medical-necessity frame when both tests are billed in the same episode . When culture is performed by an outside laboratory, the performing lab typically bills the culture; the ordering office bills the rapid test it performed.

Documenting multiple tests in one visit

When a sore-throat visit includes multiple point-of-care respiratory tests, charting should clearly distinguish which specimen was used for each test and why each was ordered. Billing discussions that address multi-test encounters highlight that payer edits and modifier needs are highly dependent on clear separation of services . Clear documentation also protects against allegations of “panel unbundling,” even when only rapid antigen tests are used.

6. Comparison Table: 87880 vs 87400 vs 87801 vs 87205

This table places 87880 in context by contrasting it with other common infectious disease diagnostic codes and methodologies. The goal is to reinforce that coding depends on target and method, and that payer edits are often method-driven.

7. Real-World Clinical Scenarios

The scenarios below show how 87880 is typically billed, what documentation supports payment, and where denials occur in real-world workflows.

Scenario 1: Pediatric visit, rapid strep positive (same-day treatment)

Setting: Pediatric office with CLIA waiver. Child has sore throat, fever, tonsillar findings.

Test: Visually read RADT performed and documented as positive.

Billing: 87880QW (Medicare/Medicaid/waiver-sensitive payers) and an appropriate E/M for the visit. The record ties the positive result to diagnosis and antibiotics. QW supports CLIA processing .

Scenario 2: Pediatric visit, rapid strep negative, reflex culture ordered

Setting: Pediatric clinic performs RADT; culture is sent to a reference lab.

Test sequence: 87880 performed and negative; clinician documents high suspicion and orders culture to confirm.

Billing logic: Office bills 87880QW. Reference lab bills the culture. Documentation explicitly states reflex culture after negative RADT, matching policy expectations for pediatric confirmation .

Scenario 3: Urgent care, strep + flu + COVID point-of-care testing

Setting: Adult with fever, myalgias, cough, and sore throat in urgent care.

Tests: Multiple POCTs performed on different specimens (nasal for flu/COVID, throat for strep).

Billing risk: Some payers apply edits when multiple rapid tests are billed together. When a denial pattern is known, modifier 59/XU may be used on secondary tests to indicate distinct services—only if documentation clearly separates specimen and target .

Scenario 4: Same-day rapid strep plus molecular strep test (denial-prone)

Setting: Office performs 87880 but also sends a molecular strep test the same day “to be sure.”

Outcome: High likelihood of denial or bundling because Medicare’s NCCI policy generally prohibits separate payment for testing the same microorganism from the same site by more than one methodology . Many commercial policies similarly disallow duplicate-method strep testing in the same episode .

Better approach: Use a single evidence-based pathway: RADT with reflex culture (peds), or NAAT alone when clinically and operationally appropriate.

Scenario 5: QW omitted on Medicare claim (avoidable denial)

Setting: CLIA-waived clinic performs a rapid strep but submits 87880 without QW.

Outcome: Claim returns denied for CLIA/waiver processing reasons.

Fix: Correct and resubmit with 87880QW and ensure CLIA number is present. CMS waiver resources are the standard reference for this requirement .

Across these scenarios, the consistent compliance themes are:

• match code to method;
• use QW when required;
• avoid duplicate-method strep testing unless clearly justified, and;
• document symptoms, result, and clinical action in a way that aligns with payer coverage logic and NCCI restrictions.